Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Work In Process (2017 - 2025)

Neurocrine Biosciences filings provide 9 years of Work In Process readings, the most recent being $13.8 million for Q1 2025.

  • On a quarterly basis, Work In Process rose 15.0% to $13.8 million in Q1 2025 year-over-year; TTM through Mar 2025 was $13.8 million, a 15.0% increase, with the full-year FY2024 number at $10.9 million, up 12.37% from a year prior.
  • Work In Process hit $13.8 million in Q1 2025 for Neurocrine Biosciences, up from $10.9 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $13.8 million in Q1 2025 to a low of $3.6 million in Q4 2021.
  • Median Work In Process over the past 5 years was $10.8 million (2024), compared with a mean of $9.8 million.
  • Biggest five-year swings in Work In Process: surged 73.21% in 2023 and later rose 12.37% in 2024.
  • Neurocrine Biosciences' Work In Process stood at $3.6 million in 2021, then skyrocketed by 55.56% to $5.6 million in 2022, then soared by 73.21% to $9.7 million in 2023, then rose by 12.37% to $10.9 million in 2024, then rose by 26.61% to $13.8 million in 2025.
  • The last three reported values for Work In Process were $13.8 million (Q1 2025), $10.9 million (Q4 2024), and $10.6 million (Q3 2024) per Business Quant data.